ArticleClinical transplantation2026
Conversion to LCP Tacrolimus Mitigates Calcineurin-Induced Nephrotoxicity in Patients After Liver Transplantation.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCalcineurin inhibitor (CNI)-induced nephrotoxicity after liver transplantation (LT) is linked to increased morbidity and mortality. LCPT offers a particular extended-release formulation, potentially improving the concentration-dose (C/D) ratio and renal outcomes. This study investigated the impact of switching from standard-release Tacrolimus (SR-Tac) to LCPT on C/D ratio and renal function.
methods170 adult LT recipients (August 2008-March 2020) treated with tacrolimus for at least two years were included. In this single-center, retrospective analysis, 63 patients converted to LCPT, while 107 patients continued on SR-Tac. Clinical data were collected every three months over 24 months.
resultsAt baseline, median C/D ratios were similar between groups (p = 0.553), the LCPT group showed significantly higher C/D ratios compared to SR-Tac during both the first (p = 0.003) and second year (p = 0.004). While LCPT-treated patients showed an increased mean estimated glomerular filtration rate (eGFR), the SR-Tac group exhibited a progressive decline at each follow-up (mean decline: -5.4 mL/min/1.73m
conclusionConversion to LCPT may improve renal function in LT recipients over two years, suggesting potential long-term nephroprotection without compromising graft function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.